Sponsor pipeline

Intergroupe Francophone du Myelome clinical trial pipeline

5 active trials 1 recruiting 1 disease areas 1 changes in 30 days

Data updated daily from ClinicalTrials.gov, last refresh 2026-10-11

What changed in the last 30 days

1 trial changed in the last 30 days: 0 stopped, 0 with notable changes, 1 with a minor change only.

Stopped: an ongoing trial was terminated, suspended or withdrawn.
Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
Minor: routine progress and housekeeping, such as sites added or enrollment closed.

Phase 3

Not charted: 3 active trials with no phase listed on ClinicalTrials.gov (typically behavioural, device, procedure and observational studies).

NCT ID	Title	Condition	Status	Updated
Phase 3
NCT06918002	Elranatamab/Lenalidomide Consolidation and/or Elranatamab Maintenance Versus Standard of…	Multiple Myeloma, Newly Diagnosed	Recruiting	2026-09-30
NCT04934475	MInimal Residual Disease Adapted Strategy	Multiple Myeloma	Active, Not Recruiting	2024-11-07
Not applicable
NCT04144387	Evaluation of the Impact of the Update SMM Criteria on the Natural History of SMM to…	Smoldering Multiple Myeloma	Active, Not Recruiting	2024-03-06
Not specified
NCT05208086	Diagnostic Performance of Spot Urine Sample for the Monoclonal Components Detection in…	Multiple Myeloma	Active, Not Recruiting	2026-04-13
NCT06062537	Analysis of Effectiveness and Safety of Teclistamab in Relapsed and Refractory Multiple…	Multiple Myeloma	Active, Not Recruiting	2026-04-13

Get alerts when Intergroupe Francophone du Myelome's trials change

Status changes, date slips, and new filings: detected daily, delivered to your inbox.